{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:08:36Z","timestamp":1792249716780,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY002162"],"award-info":[{"award-number":["P30 EY002162"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031676","name":"Institute for Mental Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001285","name":"UCL Institute of Ophthalmology, University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ajo.2025.03.039","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:29:47Z","timestamp":1743251387000},"page":"9-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of Visual Field Loss Over 4 Years in the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) Study"],"prefix":"10.1016","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9593-6412","authenticated-orcid":false,"given":"Jacque L.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-2467","authenticated-orcid":false,"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-0582","authenticated-orcid":false,"given":"Lee S.","family":"McDaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-7536","authenticated-orcid":false,"given":"Allison R.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-5375","authenticated-orcid":false,"given":"Janet K.","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Huckfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Thiran","family":"Jayasundera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naheed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-0497","authenticated-orcid":false,"given":"Brett","family":"Malbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro S.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-6599","authenticated-orcid":false,"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-1922","authenticated-orcid":false,"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zmejkoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobana","family":"Aravind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6310-5748","authenticated-orcid":false,"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-2897","authenticated-orcid":false,"given":"David G.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajo.2025.03.039_bib0001","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jmg.2009.075143","article-title":"Novel mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis pigmentosa. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't","volume":"47","author":"McGee","year":"2010","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.039_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/jmedgenet-2011-100468","article-title":"Comprehensive sequence analysis of nine Usher syndrome genes in the UK National Collaborative Usher Study. Research support, Non-U.S. Gov't","volume":"49","author":"Le Quesne Stabej","year":"2012","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.039_bib0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/jamaophthalmol.2021.0004","article-title":"Association of No-cost genetic testing program implementation and patient characteristics with access to genetic testing for inherited retinal degenerations","volume":"139","author":"Zhao","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.03.039_bib0004","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/mtna.2016.89","article-title":"Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation","volume":"5","author":"Slijkerman","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.039_bib0005","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2025.03.039_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajo.2023.02.002","article-title":"Static perimetry in the rate of progression in USH2A-related retinal degeneration (RUSH2A) study: assessment through 2 years","volume":"250","author":"Duncan","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.039_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.omtm.2019.11.016","article-title":"Genome editing in patient iPSCs corrects the most prevalent USH2A mutations and reveals intriguing mutant mRNA expression profiles","volume":"17","author":"Sanjurjo-Soriano","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.039_bib0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2020.6418","article-title":"Analysis of pathogenic variants correctable with CRISPR base editing among patients with recessive inherited retinal degeneration","volume":"139","author":"Fry","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.039_bib0009","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/genes12060805","article-title":"Generation and genetic correction of USH2A c.2299delG mutation in patient-derived induced pluripotent stem cells","volume":"12","author":"Liu","year":"2021","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.039_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.12.6.5","article-title":"Overcoming the challenges to clinical development of X-linked retinitis pigmentosa therapies: proceedings of an expert panel","volume":"12","author":"Birch","year":"2023","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"10.1016\/j.ajo.2025.03.039_bib0011","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.039_bib0012","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.039_bib0013","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ajo.2025.03.039_bib0014","series-title":"Phase 1b\/2 interim results of QR-421a RNA therapy in retinitis pigmentosa due to mutations in the USH2A gene (Stellar trial). Presentation at Euretina Virtual Congress","author":"Birch","year":"2021"},{"issue":"S267","key":"10.1016\/j.ajo.2025.03.039_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2022.205","article-title":"QR-421a RNA therapy in retinitis pigmentosa due to mutations in USH2A: stellar trial phase[AP1] 1b\/2 interim results","volume":"100","author":"Audo","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.039_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041297","article-title":"The importance of natural history studies in inherited retinal diseases","volume":"13","author":"Ayala","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.039_bib0017","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1167\/iovs.08-2009","article-title":"Disease course in patients with autosomal recessive retinitis pigmentosa due to the USH2A gene","volume":"49","author":"Sandberg","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ajo.2025.03.039_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.10.9","article-title":"Edge of Scotoma sensitivity as a microperimetry clinical trial end point in USH2A retinopathy","volume":"9","author":"Charng","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.039_bib0019","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/hmg\/ddaa004","article-title":"Clinical and preclinical therapeutic outcome metrics for USH2A-related disease","volume":"29","author":"Toms","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajo.2025.03.039_bib0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2020.05.024","article-title":"Baseline visual field findings in the RUSH2A study: associated factors and correlation with other measures of disease severity","volume":"219","author":"Duncan","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.039_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A study: best-corrected visual acuity, full-field electroretinography amplitudes, and full-field stimulus thresholds at baseline","volume":"9","author":"Birch","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.039_bib0022","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1002\/ajmg.a.62437","article-title":"Auditory and olfactory findings in patients with USH2A-related retinal degeneration-findings at baseline from the rate of progression in USH2A-related retinal degeneration natural history study (RUSH2A)","volume":"185","author":"Iannaccone","year":"2021","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ajo.2025.03.039_bib0023","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajo.2022.08.013","article-title":"Baseline microperimetry and OCT in the RUSH2A study: structure-function association and correlation with disease severity","volume":"244","author":"Lad","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.039_bib0024","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1167\/iovs.08-2229","article-title":"Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies","volume":"50","author":"Schiefer","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.039_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.4.2.14","article-title":"VFMA: topographic analysis of sensitivity data from full-field static perimetry","volume":"4","author":"Weleber","year":"2015","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.039_bib0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11517-016-1485-x","article-title":"Comparison of nonparametric methods for static visual field interpolation","volume":"55","author":"Smith","year":"2017","journal-title":"Med Biol Eng Comput"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.039_bib0027","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.039_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.039_bib0029","doi-asserted-by":"crossref","first-page":"N51","DOI":"10.1088\/0967-3334\/28\/8\/N02","article-title":"Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials","volume":"28","author":"Roman","year":"2007","journal-title":"Physiol Meas"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.039_bib0030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/jamaophthalmol.2016.0502","article-title":"Quantification of ellipsoid zone changes in retinitis pigmentosa using en face spectral domain-optical coherence tomography","volume":"134","author":"Hariri","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.039_bib0031","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.039_bib0032","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/humu.24365","article-title":"Tissue-specific genotype-phenotype correlations among USH2A-related disorders in the RUSH2A study","volume":"43","author":"Hufnagel","year":"2022","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ajo.2025.03.039_bib0033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1214\/aos\/1176342503","article-title":"Robust regression: asymptotics, conjectures and Monte Carlo","volume":"1","author":"Huber","year":"1973","journal-title":"Ann Stat"},{"key":"10.1016\/j.ajo.2025.03.039_bib0034","series-title":"SAS Conference Proceedings: SAS Users Group International","article-title":"Robust regression and outlier detection with the ROBUSTREG procedure","author":"Chen","year":"2002"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.039_bib0035","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1167\/iovs.08-2843","article-title":"The glaucoma research community and FDA look to the future: a report from the NEI\/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium","volume":"50","author":"Weinreb","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.03.039_bib0036","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2022.07.013","article-title":"Visual field endpoints for neuroprotective trials: a case for AI-driven patient enrichment","volume":"243","author":"Chen","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.039_bib0037","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1364\/BOE.2.001106","article-title":"Method for deriving visual field boundaries from OCT scans of patients with retinitis pigmentosa","volume":"2","author":"Hood","year":"2011","journal-title":"Biomed Opt Express"},{"key":"10.1016\/j.ajo.2025.03.039_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2020.05.024","article-title":"Baseline visual field findings in the RUSH2A study: associated factors and correlation with other measures of disease severity","volume":"219","author":"Duncan","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.039_bib0039","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ophtha.2014.11.005","article-title":"Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa","volume":"122","author":"Birch","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.039_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1167\/iovs.11-8410","article-title":"Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thicknesses in patients with retinitis pigmentosa","volume":"53","author":"Wen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.03.039_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajo.2018.10.003","article-title":"Natural history study of retinal structure, progression, and symmetry using ellipzoid zone metrics in RPGR-associated retinopathy","volume":"198","author":"Tee","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.039_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148022","article-title":"Structure-function modeling of optical coherence tomography and standard automated perimetry in the retina of patients with autosomal dominant retinitis pigmentosa","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ajo.2025.03.039_bib0043","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/ejhg.2014.283","article-title":"A detailed clinical and molecular survey of subjects with nonsyndromic USH2A retinopathy reveals an allelic hierarchy of disease-causing variants. Research support, Non-U.S. Gov't","volume":"23","author":"Lenassi","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.039_bib0044","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2016.01.021","article-title":"Visual prognosis in USH2A-associated retinitis pigmentosa is worse for patients with Usher syndrome type IIa than for those with nonsyndromic retinitis pigmentosa","volume":"123","author":"Pierrache","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.039_bib0045","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1111\/aos.14626","article-title":"Correlation between genotype and phenotype in 69 Chinese patients with USH2A mutations: a comparative study of the patients with Usher Syndrome and Nonsyndromic Retinitis Pigmentosa","volume":"99","author":"Meng","year":"2021","journal-title":"Acta Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:45:29Z","timestamp":1762080329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":45,"alternative-id":["S000293942500159X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.039","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Visual Field Loss Over 4 Years in the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}